Biotech · Private company
Pieris Pharmaceuticals, Inc.
Track this companyFree. Adds Pieris Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxelPhase 2 · HER2-positive Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
- Cinrebafusp alfa (PRS-343) in combination with tucatinibPhase 2 · HER2-positive Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
- PRS-343Phase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PRS-343 in Combination with AtezolizumabPhase 1 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ AndenocarinomaPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 1, 2021ClinicalTrials.gov NCT05190445 · fetched Nov 12, 2026
- PRS-343 in Combination With Atezolizumab in HER2-Positive Solid TumorsPHASE1 · COMPLETED · started Aug 21, 2018ClinicalTrials.gov NCT03650348 · fetched Nov 12, 2026
- PRS-343 in HER2-Positive Solid TumorsPHASE1 · COMPLETED · started Sep 13, 2017ClinicalTrials.gov NCT03330561 · fetched Nov 12, 2026